Kurt Gish is a biotech founder and scientific executive currently serving as the Chief Scientific Officer at BioLoomics. With over 25 years of experience, Gish has played a pivotal role in developing discovery platforms and driving innovative antibody and ADC programs from inception to Phase I clinical trials. Previously, Gish held leadership positions at AbbVie, PDL BioPharma, and Trilo Therapeutics, among others, focusing on first-in-class therapeutic developments for oncology and autoimmune diseases. Gish also contributes to the Scientific Advisory Board of the Myeloma Investment Fund, evaluating biotech companies for investment opportunities. Gish earned a B.S. in Biology from UC Irvine and a Ph.D. in Biology from Stanford University, along with a Post-Doctoral Fellowship in Molecular Immunology.
Location
San Francisco, United States
Links
This person is not in any teams
This person is not in any offices